Evidence map›Paper›PMID 28827421›Full record

ArticleAntimicrobial agents and chemotherapy2017

Prevalence of Slow-Growth Vancomycin Nonsusceptibility in Methicillin-Resistant Staphylococcus aureus.

Yuki Katayama, Takuya Azechi, Motoyasu Miyazaki, Tohru Takata, Miwa Sekine, Hidehito Matsui, Hideaki Hanaki, Koji Yahara, Hiroshi Sasano, Kota Asakura and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Vancomycin Resistance inMicroorganisms · 2022
    Review
  7. Loratadine inhibitsiScience · 2022
    Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Antibiotic Resistance and the MRSA Problem.Microbiology spectrum · 2019
    Review
  14. Article
  15. Heterogeneous Vancomycin-IntermediateFrontiers in microbiology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 2 countries.

Yuki KatayamaDepartment of Microbiology, Faculty of Medicine, Juntendo University, Tokyo, Japan yukk@juntendo.ac.jp.
Takuya AzechiDepartment of Pharmacy, Juntendo University Hospital, Tokyo, Japan.
Motoyasu MiyazakiDepartment of Pharmacy, Fukuoka University Chikushi Hospital, Chikushino, Japan.
Tohru TakataDepartment of Infection Control, Fukuoka University Hospital, Fukuoka, Japan.
Miwa SekineDepartment of Microbiology, Faculty of Medicine, Juntendo University, Tokyo, Japan.
Hidehito MatsuiInfection Control Research Center, Kitasato Institute for Life Science, Kitasato University, Tokyo, Japan.
Hideaki HanakiInfection Control Research Center, Kitasato Institute for Life Science, Kitasato University, Tokyo, Japan.
Koji YaharaDepartment of Bacteriology II, National Institute of Infectious Diseases, Tokyo, Japan.
Hiroshi SasanoDepartment of Pharmacy, Juntendo University Hospital, Tokyo, Japan.
Kota AsakuraDepartment of Pharmacy, Juntendo University Hospital, Tokyo, Japan.
Tomoiku TakakuDivision of Hematology, Department of Internal Medicine, Juntendo University, Tokyo, Japan.
Tomonori OchiaiDivision of Hematology, Department of Internal Medicine, Juntendo University, Tokyo, Japan.
Norio KomatsuDivision of Hematology, Department of Internal Medicine, Juntendo University, Tokyo, Japan.
Henry F ChambersDepartment of Medicine, University of California San Francisco, San Francisco, California, USA.
Juntendo University · JPJuntendo University Hospital · JPKitasato University · JPFukuoka University · JPFukuoka University Hospital · JPNational Institute of Infectious Diseases · JPUniversity of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously reported a novel phenotype of vancomycin-intermediate

Indexed as

Anti-Bacterial AgentsDNA-Directed RNA PolymerasesHigh-Throughput Nucleotide SequencingHumansMethicillin-Resistant Staphylococcus aureusMicrobial Sensitivity TestsMupirocinMutationPolymorphism, Single NucleotideVancomycinVancomycin ResistanceAnti-Bacterial AgentsDNA-Directed RNA PolymerasesMupirocinVancomycinHA-MRSAhVISAMRSAmupirocinppGpprecurrent infectionslow VISAstringent responsetolerancevancomycin resistance

Identifiers

PMID28827421
PMCPMC5655046
OpenAlexW2748541813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.